Research news

Exenatide-PD3 results published

The full results of the Exenatide-PD3 study, a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon), have now been published. They report that the study unfortunately did not meet its primary or secondary endpoints. The full results of the Exenatide-PD3 study have…


How testing the gut could help in the early detection of Parkinson’s

Recent results from a Cure Parkinson’s funded study have provided more evidence for a possible role of the gut in Parkinson’s, as well as identifying new markers to aid in early detection of the condition. There is growing evidence to suggest that the gut may…


News Research news

Insights on grant applications and research funding from our latest Research Committee interns  

At the end of 2023, Cure Parkinson’s set up an internship scheme for PhD students or early post-doctoral researchers to join our Research Committee for a one-year period. This committee is responsible for rigorously reviewing each of our funding applications to ensure they are scientifically robust…


Our latest pre-clinical research project: evaluating the neuroprotective properties of ‘CP-6’

Cure Parkinson’s is excited to announce funding for a new pre-clinical study of ‘CP-6’ for Parkinson’s led by Dr Marco Fazzari and his team at the University of Pittsburgh. CP-6 is a new drug being developed by Creegh Pharmaceuticals. Early lab-based studies have suggested that…


News Research news

2024 Tom Isaacs Award honours Parkinson’s expert Professor Oliver Bandmann

Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Professor Oliver Bandmann as the winner of the 2024 Tom Isaacs Award, which honours researchers who closely collaborate with the Parkinson’s community. The award was virtually presented to Professor Bandmann as part of the…